Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy vs Upfront Surgery for Resectable Pancreatic and Periampullary Cancer
NCT07081360Phase 3Recruiting
- Sponsor
- Minia University
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mFOLFIRINOX in pancreatic cancer (PC), periampullary cancer, sponsored by Minia University. Started Jul 2025; status: recruiting.
02
Drugs
mFOLFIRINOX
03
Conditions
pancreatic cancer (PC)periampullary cancer
Beyond the preview
Go deeper on NCT07081360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081360.